Loading clinical trials...
Loading clinical trials...
A 2-year Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Wet AMD
Conditions
Interventions
EYP-1901
Aflibercept (2.0 mg)
Locations
79
United States
Retinal Research Institute, LLC
Phoenix, Arizona, United States
Retina Partners of Northwest Arkansas
Springdale, Arkansas, United States
California Retina Consultants
Bakersfield, California, United States
Retina Vitreous Associates Medical Group
Beverly Hills, California, United States
Macula and Retina Institute
Glendale, California, United States
Retina Consultants San Diego
Poway, California, United States
Start Date
October 22, 2024
Primary Completion Date
August 1, 2026
Completion Date
August 1, 2027
Last Updated
April 2, 2026
NCT05407636
NCT06718816
NCT06704009
NCT06683742
NCT07255885
NCT06969001
Lead Sponsor
EyePoint Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions